Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 28, 2022

Consequences of CDK4/6 Inhibitor Discontinuation in Patients With Metastatic Breast Cancer on Endocrine Treatment During the COVID-19 Outbreak

Clinical Breast Cancer


Additional Info

Clinical Breast Cancer
Consequences of Discontinuing a 4/6 Cyclin D-Dependent Kinase Inhibitor During Endocrine Treatment in Hormone-Sensitive Metastatic Breast Cancer Patients in the Context of the COVID-19 Outbreak
Clin. Breast Cancer 2023 Jan 01;23(1)32-37, S Martin, C Pflumio, P Trensz, F Schaff-Wendling, MK Weindling, C Fischbach, L Pierard, JM Limacher, R Nader, M Velten, T Petit

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading